Angiochem to Present at EANO 2016 Meeting

MONTREAL, QC--(Marketwired - October 11, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an oral presentation during the Non Glioma session at the European Association of Neuro Oncology (EANO) 2016 Meeting in Mannheim Germany from October 12-16, 2016. Angiochem's presentation will take place on October 16th.

"We are honored to have been chosen to present at EANO," said John Huss, Executive Chairman of Angiochem. "It is a premiere conference that brings together oncology professionals from around the globe to share updates on ground-breaking cancer research, and as such, we look forward to sharing our insights at this important event."

Angiochem is focused on developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases.

Date: October 16
Time: 11:00 - 12:30 pm
Presenter: Dr. Priya Kumthekar, MD
Abstract #: OS7.2
Title: A phase II study of ANG1005, a novel BBB/BCB penetrant taxane in patients with recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit

http://www.angiochem.com.